{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:47:13Z","timestamp":1785833233398,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"DOI":"10.7759\/cureus.113923","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:23:57Z","timestamp":1785831837000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Response and Survival With Liposomal Irinotecan and Fluorouracil in a Patient With Locally Advanced Pancreatic Ductal Adenocarcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Skaiste","family":"Tulyte-Kirzova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvina","family":"Vitkauskaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liutauras","family":"Gumbys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla P","year":"2019","unstructured":"Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019, 10:10-27. 10.14740\/wjon1166","journal-title":"World J Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1345-6","article-title":"Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches","volume":"14","author":"Orth M","year":"2019","unstructured":"Orth M, Metzger P, Gerum S, et al.. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019, 14:141. 10.1186\/s13014-019-1345-6","journal-title":"Radiat Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook CJ","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023, 186:1729-54. 10.1016\/j.cell.2023.02.014","journal-title":"Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel RL","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022, 72:7-33. 10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy T","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, et al.. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023, 34:987-1002. 10.1016\/j.annonc.2023.08.009","journal-title":"Ann Oncol"},{"key":"ref6","unstructured":"Pancreatic adenocarcinoma. (2026). https.\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1455."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam A","year":"2019","unstructured":"Wang-Gillam A, Hubner RA, Siveke JT, et al.. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019, 108:78-87. 10.1016\/j.ejca.2018.12.007","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI- 1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam A","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, et al.. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI- 1): a global, randomised, open-label, phase 3 trial. Lancet. 2016, 387:545-57. 10.1016\/S0140-6736(15)00986-1","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104386","article-title":"Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis","volume":"201","author":"Chen BS","year":"2024","unstructured":"Chen BS, Chan SY, Bteich F, Kuang C, Meyerhardt JA, Ma KS. Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2024, 201:104386. 10.1016\/j.critrevonc.2024.104386","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5893","article-title":"Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic\/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel","volume":"27","author":"Surinach A","year":"2020","unstructured":"Surinach A, Phung T, Abdul-Rahim O, Khushman M. Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic\/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel. Curr Oncol. 2020, 27:e222-5. 10.3747\/co.27.5893","journal-title":"Curr Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000521315","article-title":"Consistent response on challenge and rechallenge of liposomal irinotecan in a patient with metastatic pancreatic adenocarcinoma previously treated with gemcitabine plus Nab-paclitaxel: a case report","volume":"14","author":"Kim SR","year":"2021","unstructured":"Kim SR, Lee HJ, Kim D. Consistent response on challenge and rechallenge of liposomal irinotecan in a patient with metastatic pancreatic adenocarcinoma previously treated with gemcitabine plus Nab-paclitaxel: a case report. Case Rep Oncol. 2021, 14:1882-8. 10.1159\/000521315","journal-title":"Case Rep Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20064895","article-title":"Quality of life in patients with pancreatic cancer: a literature review","volume":"20","author":"Cipora E","year":"2023","unstructured":"Cipora E, Czerw A, Partyka O, et al.. Quality of life in patients with pancreatic cancer: a literature review. Int J Environ Res Public Health. 2023, 20:4895. 10.3390\/ijerph20064895","journal-title":"Int J Environ Res Public Health"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa121","article-title":"Clinical characteristics of patients with pancreatic cancer and pathogenic ATM alterations","volume":"5","author":"Hannan Z","year":"2021","unstructured":"Hannan Z, Yu S, Domchek S, Mamtani R, Reiss KA. Clinical characteristics of patients with pancreatic cancer and pathogenic ATM alterations. JNCI Cancer Spectr. 2021, 5:pkaa121. 10.1093\/jncics\/pkaa121","journal-title":"JNCI Cancer Spectr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2005.04.040","article-title":"Role of pharmacogenetics in irinotecan therapy","volume":"234","author":"de Jong FA","year":"2006","unstructured":"de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH. Role of pharmacogenetics in irinotecan therapy. Cancer Lett. 2006, 234:90-106. 10.1016\/j.canlet.2005.04.040","journal-title":"Cancer Lett"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.06.019","article-title":"Topoisomerase expression and amplification in solid tumours: analysis of 24,262 patients","volume":"83","author":"Heestand GM","year":"2017","unstructured":"Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R. Topoisomerase expression and amplification in solid tumours: analysis of 24,262 patients. Eur J Cancer. 2017, 83:80-7. 10.1016\/j.ejca.2017.06.019","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1414754","article-title":"Expression of topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer","volume":"19","author":"Shaojun C","year":"2018","unstructured":"Shaojun C, Li H, Haixin H, Guisheng L. Expression of topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. Cancer Biol Ther. 2018, 19:153-9. 10.1080\/15384047.2017.1414754","journal-title":"Cancer Biol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/482129-long-term-response-and-survival-with-liposomal-irinotecan-and-fluorouracil-in-a-patient-with-locally-advanced-pancreatic-ductal-adenocarcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:23:59Z","timestamp":1785831839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/482129-long-term-response-and-survival-with-liposomal-irinotecan-and-fluorouracil-in-a-patient-with-locally-advanced-pancreatic-ductal-adenocarcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.113923","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}